Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680911 · ClinicalTrials.gov registry record · Phase 3
NAC for Head Trauma-induced Anosmia
A Phase 3 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT03680911: Clinical Trial Phase 3 study, sponsored by University of Miami.
NCT03680911 is a Phase 3 study that was terminated before completion, run by University of Miami. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680911, a Phase 3 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will compare administration of N-Acetyl Cysteine (NAC) versus placebo for the treatment of olfactory loss due to head injury. The hypothesis is that treatment with NAC acutely after head injury will result in improved olfactory function
Primary Outcome
Olfactory function will be measured using the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a self-administered 40-item test involving microencapsulated (scratch-and-sniff) odors with a forced-choice design. The total score ranges from 0-40 with the higher score indicating better olfactory function.
Interventions
- DRUG Placebo oral capsule
- DRUG N Acetyl Cysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-10-12 |
| Est. Completion | 2020-01-07 |
| Phase | Phase 3 |
Why NCT03680911 stopped before completion
NCT03680911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03680911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03680911 about?
NCT03680911 is a clinical study titled "NAC for Head Trauma-induced Anosmia". This study will compare administration of N-Acetyl Cysteine (NAC) versus placebo for the treatment of olfactory loss due to head injury. The hypothesis is that treatment with NAC acutely after head injury will result in improved olfactory function
What is the current status of trial NCT03680911?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2018-10-12. Estimated completion is 2020-01-07.
What interventions are being tested in trial NCT03680911?
The interventions under investigation include: Placebo oral capsule (DRUG), N Acetyl Cysteine (DRUG).
Who is sponsoring clinical trial NCT03680911?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03680911's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI